Selurampanel structure
|
Common Name | Selurampanel | ||
|---|---|---|---|---|
| CAS Number | 912574-69-7 | Molecular Weight | 377.42 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H19N5O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SelurampanelSelurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research[1][2]. |
| Name | N-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1H-quinazolin-3-yl]methanesulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Selurampanel (Compound 1S) potently and dose-dependently antagonizes maximal electroshock seizure (MES)-induced generalized tonic-clonic seizures in mice with an ED50 value around 7 mg/kg after 1 h pre-treatment[1]. In a study with a 3 mg/kg i.v. dose, a mouse plasma half-life of 3.3 h is determined, with a moderate volume of distribution (Vdss=1.3 L/kg) and a low clearance of 5.4 mL/min▪kg[1]. |
| References |
| Molecular Formula | C16H19N5O4S |
|---|---|
| Molecular Weight | 377.42 |
| Exact Mass | 377.11600 |
| PSA | 127.49000 |
| LogP | 2.28290 |
| UNII-7WG1MR7DAR |
| Selurampanel |
| Methanesulfonamide,N-(1,4-dihydro-7-(1-methylethyl)-6-(1-methyl-1H-pyrazol-5-yl)-2,4-dioxo-3(2H)-quinazolinyl) |
| Selurampanel [INN] |